Pharmaceutical Raw Materials Erlotinib Hydrochloride for Treat Cancer Erlotinib

Pharmaceutical Raw Materials Erlotinib Hydrochloride for Treat Cancer 183321-74-6

Erlotinib Hydrochloride Application

Erlotinib hydrochloride (the trade name Tarceva) is a directly acting inhibitor of epidermal GW receptor (EGFR/HER-1) tyrosine kinase with an IC50 of 2 nM.

Epidermal GF receptor (EGFR) is one member of the ErbB family which includes EGFR (ErbB1), ErbB2, ErbB3 and ErbB4. The activation of EGFR is dependent on the binding of peptide GF to the receptor. In many carcinomas, the presence of EGFR mutation leads to the activation of EGFP, which causes cell proliferation and other cancer processes.

Selective inhibition of EGFR tyrosine kinase by erlotinib hydrochloride leads to the disruption of cancer growth and development which include cell migration, proliferation, angiogenesis, and apoptosis. For instance, erlotinib hydrochloride was shown to induce cell apoptosis and G0/G1 cell cycle arrest in hepatocellular cancer cells, Bxpc-3 and PANC-1 cells, thereby enhancing chemosensitivity towards cytostatics.

In addition, this product is widely researched and used for the treatment of human advanced non-small cell lung cancer (NSCLC). In pancreatic cancer, erlotinib hydrochloride was also reported to exhibit an anti-tumour effect.

Erlotinib Hydrochloride Use in Cancer

Erlotinib hydrochloride is approved to be used alone or with other drugs to treat:

Non-small cell lung cancer (NSCLC).
It is used as first-line treatment for metastatic NSCLC in patients with tumors that have certainepidermal GW receptor (EGFR) mutations.

It is used for locally advanced or metastatic NSCLC in patients who have already been treated with chemotherapy.

Pancreatic cancer. It is used with gemcitabine hydrochloride in patients whose disease cannot be removed by surgery or has metastasized.

Erlotinib hydrochloride is also being studied in the treatment of other types of cancer.
  Pharmaceutical Raw Materials Erlotinib Hydrochloride for Treat Cancer 183321-74-6

Erlotinib Hydrochloride Application

Erlotinib hydrochloride (the trade name Tarceva) is a directly acting inhibitor of epidermal GW receptor (EGFR/HER-1) tyrosine kinase with an IC50 of 2 nM.

Epidermal GF receptor (EGFR) is one member of the ErbB family which includes EGFR (ErbB1), ErbB2, ErbB3 and ErbB4. The activation of EGFR is dependent on the binding of peptide GF to the receptor. In many carcinomas, the presence of EGFR mutation leads to the activation of EGFP, which causes cell proliferation and other cancer processes.

Selective inhibition of EGFR tyrosine kinase by erlotinib hydrochloride leads to the disruption of cancer growth and development which include cell migration, proliferation, angiogenesis, and apoptosis. For instance, erlotinib hydrochloride was shown to induce cell apoptosis and G0/G1 cell cycle arrest in hepatocellular cancer cells, Bxpc-3 and PANC-1 cells, thereby enhancing chemosensitivity towards cytostatics.

In addition, this product is widely researched and used for the treatment of human advanced non-small cell lung cancer (NSCLC). In pancreatic cancer, erlotinib hydrochloride was also reported to exhibit an anti-tumour effect.

Erlotinib Hydrochloride Use in Cancer

Erlotinib hydrochloride is approved to be used alone or with other drugs to treat:

Non-small cell lung cancer (NSCLC).
It is used as first-line treatment for metastatic NSCLC in patients with tumors that have certainepidermal GW receptor (EGFR) mutations.

It is used for locally advanced or metastatic NSCLC in patients who have already been treated with chemotherapy.

Pancreatic cancer. It is used with gemcitabine hydrochloride in patients whose disease cannot be removed by surgery or has metastasized.

Erlotinib hydrochloride is also being studied in the treatment of other types of cancer.